Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01557959Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00499655Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerTreatment
NCT00062101Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung CancerTreatment
NCT00087412S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerTreatment